LumiraDx
The pharma giant will also pay $55 million to fund the point-of-care diagnostics platform until the acquisition closes, which is expected to occur by mid-2024.
Disease detection company Cardiosense, sustainable pill bottle maker Cabinet Health, testing company LumiraDx and physician engagement platform KeyOps also garner investments.
The nasal swab test device returns results in 12 minutes.